tiprankstipranks
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
US Market
OLMA
Olema Pharmaceuticals
RESEARCH TOOLSreports
Want to see OLMA full AI Analyst Report?

Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

969 Followers
See the Price Targets and Ratings of:

OLMA Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Olema
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OLMA Stock 12 Month Forecast

Average Price Target

$39.75
▲(136.33% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Olema Pharmaceuticals in the last 3 months. The average price target is $39.75 with a high forecast of $62.00 and a low forecast of $23.00. The average price target represents a 136.33% change from the last price of $16.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","18":"$18","33":"$33","48":"$48","63":"$63"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$62.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,18,33,48,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,17.987692307692306,21.655384615384616,25.323076923076925,28.99076923076923,32.65846153846154,36.326153846153844,39.99384615384616,43.66153846153846,47.32923076923077,50.996923076923075,54.66461538461539,58.332307692307694,{"y":62,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,16.276153846153846,18.232307692307693,20.18846153846154,22.144615384615385,24.10076923076923,26.056923076923077,28.013076923076923,29.96923076923077,31.925384615384615,33.88153846153846,35.83769230769231,37.793846153846154,{"y":39.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,14.987692307692308,15.655384615384616,16.323076923076922,16.99076923076923,17.658461538461538,18.326153846153847,18.993846153846153,19.661538461538463,20.32923076923077,20.99692307692308,21.664615384615384,22.332307692307694,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$62.00Average Price Target$39.75Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on OLMA
Yigal Nochomovitz
Citi
Citi
$62
Buy
268.61%
Upside
Reiterated
05/14/26
Citi opens 'upside 90-day catalyst watch' on Olema OncologyCiti opens 'upside 90-day catalyst watch' on Olema Oncology
Oppenheimer Analyst forecast on OLMA
Matthew Biegler
Oppenheimer
Oppenheimer
$48
Buy
185.37%
Upside
Reiterated
05/13/26
Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
LifeSci Capital Analyst forecast on OLMA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$29
Buy
72.41%
Upside
Reiterated
05/12/26
Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), Opus Genetics (IRD)
TD Cowen Analyst forecast on OLMA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/12/26
Olema Pharmaceuticals: Differentiated KAT6i and Palazestrant Pipeline Catalysts Underpin Buy Rating
J.P. Morgan Analyst forecast on OLMA
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
05/12/26
Olema Pharmaceuticals: Citi’s Anupam Rama Reiterates Buy on Underappreciated Palazestrant Upside and Long-Term Pipeline Catalysts
H.C. Wainwright Analyst forecast on OLMA
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$38
Buy
125.92%
Upside
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Goldman Sachs Analyst forecast on OLMA
Richard Law CFA
Goldman Sachs
Goldman Sachs
$27→$23
Buy
36.74%
Upside
Reiterated
05/12/26
Goldman Sachs Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
Piper Sandler Analyst forecast on OLMA
Kelsey Goodwin
Piper Sandler
Piper Sandler
$40
Buy
137.81%
Upside
Reiterated
04/20/26
Piper Sandler Remains a Buy on Olema Pharmaceuticals (OLMA)
Wolfe Research Analyst forecast on OLMA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Initiated
03/26/26
Olema Oncology initiated with a Peer Perform at Wolfe ResearchOlema Oncology initiated with a Peer Perform at Wolfe Research
Jefferies Analyst forecast on OLMA
Dennis Ding
Jefferies
Jefferies
$43→$40
Buy
137.81%
Upside
Initiated
03/19/26
Olema Oncology assumed with a Buy at JefferiesOlema Oncology assumed with a Buy at Jefferies
Guggenheim Analyst forecast on OLMA
Bradley Canino
Guggenheim
Guggenheim
$40→$38
Buy
125.92%
Upside
Reiterated
03/16/26
Guggenheim Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
Stifel Nicolaus Analyst forecast on OLMA
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$48
Buy
185.37%
Upside
Initiated
02/11/26
Olema Oncology initiated with a Buy at StifelOlema Oncology initiated with a Buy at Stifel
UBS Analyst forecast on OLMA
Michael Yee
UBS
UBS
$45
Buy
167.54%
Upside
Initiated
01/06/26
Olema Oncology initiated with a Buy at UBSOlema Oncology initiated with a Buy at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on OLMA
Yigal Nochomovitz
Citi
Citi
$62
Buy
268.61%
Upside
Reiterated
05/14/26
Citi opens 'upside 90-day catalyst watch' on Olema OncologyCiti opens 'upside 90-day catalyst watch' on Olema Oncology
Oppenheimer Analyst forecast on OLMA
Matthew Biegler
Oppenheimer
Oppenheimer
$48
Buy
185.37%
Upside
Reiterated
05/13/26
Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
LifeSci Capital Analyst forecast on OLMA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$29
Buy
72.41%
Upside
Reiterated
05/12/26
Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), Opus Genetics (IRD)
TD Cowen Analyst forecast on OLMA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/12/26
Olema Pharmaceuticals: Differentiated KAT6i and Palazestrant Pipeline Catalysts Underpin Buy Rating
J.P. Morgan Analyst forecast on OLMA
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
05/12/26
Olema Pharmaceuticals: Citi’s Anupam Rama Reiterates Buy on Underappreciated Palazestrant Upside and Long-Term Pipeline Catalysts
H.C. Wainwright Analyst forecast on OLMA
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$38
Buy
125.92%
Upside
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Goldman Sachs Analyst forecast on OLMA
Richard Law CFA
Goldman Sachs
Goldman Sachs
$27→$23
Buy
36.74%
Upside
Reiterated
05/12/26
Goldman Sachs Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
Piper Sandler Analyst forecast on OLMA
Kelsey Goodwin
Piper Sandler
Piper Sandler
$40
Buy
137.81%
Upside
Reiterated
04/20/26
Piper Sandler Remains a Buy on Olema Pharmaceuticals (OLMA)
Wolfe Research Analyst forecast on OLMA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Initiated
03/26/26
Olema Oncology initiated with a Peer Perform at Wolfe ResearchOlema Oncology initiated with a Peer Perform at Wolfe Research
Jefferies Analyst forecast on OLMA
Dennis Ding
Jefferies
Jefferies
$43→$40
Buy
137.81%
Upside
Initiated
03/19/26
Olema Oncology assumed with a Buy at JefferiesOlema Oncology assumed with a Buy at Jefferies
Guggenheim Analyst forecast on OLMA
Bradley Canino
Guggenheim
Guggenheim
$40→$38
Buy
125.92%
Upside
Reiterated
03/16/26
Guggenheim Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
Stifel Nicolaus Analyst forecast on OLMA
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$48
Buy
185.37%
Upside
Initiated
02/11/26
Olema Oncology initiated with a Buy at StifelOlema Oncology initiated with a Buy at Stifel
UBS Analyst forecast on OLMA
Michael Yee
UBS
UBS
$45
Buy
167.54%
Upside
Initiated
01/06/26
Olema Oncology initiated with a Buy at UBSOlema Oncology initiated with a Buy at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Olema Pharmaceuticals

3 Months
xxx
Success Rate
11/17 ratings generated profit
65%
Average Return
+46.35%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +46.35% per trade.
1 Year
Emily BodnarH.C. Wainwright
Success Rate
18/30 ratings generated profit
60%
Average Return
+119.82%
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +119.82% per trade.
2 Years
xxx
Success Rate
14/17 ratings generated profit
82%
Average Return
+83.89%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +83.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OLMA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
18
11
20
15
19
Buy
11
9
4
2
3
Hold
0
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
20
25
18
23
In the current month, OLMA has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. OLMA average Analyst price target in the past 3 months is 39.75.
Each month's total comprises the sum of three months' worth of ratings.

OLMA Financial Forecast

OLMA Earnings Forecast

Next quarter’s earnings estimate for OLMA is -$0.55 with a range of -$0.63 to -$0.45. The previous quarter’s EPS was -$0.52. OLMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.
Next quarter’s earnings estimate for OLMA is -$0.55 with a range of -$0.63 to -$0.45. The previous quarter’s EPS was -$0.52. OLMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.
No data currently available

OLMA Sales Forecast

Next quarter’s sales forecast for OLMA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. OLMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.
Next quarter’s sales forecast for OLMA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. OLMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.

OLMA Stock Forecast FAQ

What is OLMA’s average 12-month price target, according to analysts?
Based on analyst ratings, Olema Pharmaceuticals’s 12-month average price target is 39.75.
    What is OLMA’s upside potential, based on the analysts’ average price target?
    Olema Pharmaceuticals has 136.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is OLMA a Buy, Sell or Hold?
          Olema Pharmaceuticals has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Olema Pharmaceuticals’s price target?
            The average price target for Olema Pharmaceuticals is 39.75. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $62.00 ,the lowest forecast is $23.00. The average price target represents 136.33% Increase from the current price of $16.82.
              What do analysts say about Olema Pharmaceuticals?
              Olema Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of OLMA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.